mk-0249
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00420420)
Timeline
Indications
Mechanism of action
- Histamine H3 receptorINVERSE AGONIST
HRH3 inverse agonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1- Mol. weight
- 431.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL476323 ↗
Also known as
- mk0249
- mk0249
- mk-0249
- mk-0249
- mk-0249
- mk-0249
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00874939 | Phase 1 | Apr 1, 2009 | Merck |
| NCT00620659 | Phase 2 | Feb 1, 2008 | Merck |
| NCT00506077 | Phase 2 | Dec 1, 2007 | Merck |
| NCT00475735 | Phase 2 | Jul 1, 2007 | Merck |
| NCT00420420 | Phase 2 | Nov 1, 2006 | Merck |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 5 | 5 | 2 | 2006 |
1 organizations
Page 1 / 1